WA
TVTX icon

Whipplewood Advisors’s Travere Therapeutics TVTX Stock Holding History

Whipplewood Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3
Closed -$627 – 1268
2025
Q1 		$627 Sell
3
-94
-97% -$1.91K ﹤0.01% 1097
2024
Q4 		$1.69K Buy
+97
New +$1.72K ﹤0.01% 911

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Whipplewood Advisors's TVTX Position: Q2 2025 in Review

Whipplewood Advisors sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 3 shares — an estimated $627 sold.

Whipplewood Advisors first reported a position in TVTX in Q4 2024 and held it in 2 quarters. The position peaked at $1.69K in Q4 2024. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • Whipplewood Advisors reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Whipplewood Advisors sold 3 Travere Therapeutics shares in Q2 2025, an estimated $627.
  • Whipplewood Advisors first reported a position in Travere Therapeutics in Q4 2024 and held it in 2 quarters.
  • Whipplewood Advisors's Travere Therapeutics position peaked at $1.69K in Q4 2024.
  • 211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on Whipplewood Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.